Navigation Links
Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
Date:6/1/2011

HOBOKEN, N.J. and PHILADELPHIA, June 1, 2011 /PRNewswire/ -- Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL. NKP-1339 is a novel transferrin targeted ruthenium based anti-cancer compound. The intracellular targets of NKP-1339 include GRP78, a key regulator of mis-folded protein processing. In preclinical studies, in vivo and in vitro activity has been demonstrated against multiple tumor types, including those resistant to other anti-cancer agents.

The NKP-1339 Phase I trial is a dose-ascending trial and determines the safety, tolerability, maximum tolerated dose (MTD) and pharmacokinetics of NKP-1339. A total of 16 patients with metastatic solid tumors resistant to standard therapies have been treated to date at six different dose levels. NKP-1339 treatment has been generally well tolerated, with the most common drug related side effects of grade 1-2 fever and mild flu-like symptoms. MTD has not been reached and NKP-1339 dose escalation continues. Signs of anti-tumor activity (stable disease greater than or equal to four months; tumor regression) have been observed. A patient with a neuroendocrine tumor (NET) of the small intestine has been on NKP-1339 therapy for over 13 months with a continuing minor response. The patient remains on NKP-1339 therapy. Another patient with the metastatic gastrinoma NET exhibited six months stable disease, and two patients with metastatic non-small cell lung cancer exhibited four months stable disease.

The NKP-1339 Phase I trial is being led by Dr. Daniel Von Hoff, Translational Genomics Institute, Arizona, and Dr. Howard Burris, Sarah Canon Research Institute, Tennessee. Reflecting on NKP-1339's novel mechanism of action, Dr. Von Hoff noted "Resistance to anti-cancer therapy remains a major challenge in treatment of patients with metastatic cancer. First-
'/>"/>

SOURCE Niiki Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
2. Centella Therapeutics Licenses Novel New Drug Designed to Enhance the Effectiveness of Cancer Treatment
3. Novel Device Shows Promise for Reducing HIV Among Men
4. CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
5. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
6. International Leaders in Electrophysiology Discuss Improving Atrial Fibrillation Treatment Using Novel Endoscopically Guided Laser Ablation Catheter
7. MonoSol Rx and KemPharm to Develop Novel PharmFilm® Product for ADHD
8. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
9. Shrink Nanotechnologies Announces That Critical Cell Align Tissue Engineering Platform Patent as Well as IP on a Novel Immunoassay Substrate Material Has Been Filed With the USPTO
10. Theramed Secures Exclusive Canadian Distribution Rights for Two Novel Obstetrics Products from Glenveigh
11. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 3, 2015  Diomics today announced that ... senior official, has joined the company,s board of directors, ... Intelligence Studies Project and Clinical Professor at the Lyndon ... of Texas at Austin. "Steve brings ... served 28 years as a member of CIA,s clandestine ...
(Date:6/3/2015)... CORONA, Calif. , June 3, 2015  Giving ... is the ultimate mission of the International Academy ... offer treatments and resources that are at the forefront ... eye care professionals in the technology and latest treatment ... that has not been remedied with traditional means. Recently, ...
(Date:6/3/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/t3kkhg/the_future_of ) has ... of Pharmaceutical Outsourcing" report to their offering. ... need to develop better drugs with high success ... increasingly utilizing external resources to increase their efficiency ... internal operation. Their outsourcing demands and proportions have ...
Breaking Medicine Technology:Former CIA Clandestine Service Senior Official Stephen B. Slick joins Diomics Board of Directors 2International Academy of Low Vision Specialists Announces Training of Doctors in Six New States and Canada 2International Academy of Low Vision Specialists Announces Training of Doctors in Six New States and Canada 3International Academy of Low Vision Specialists Announces Training of Doctors in Six New States and Canada 4The Future of Pharmaceutical Outsourcing: 2015 Report 2
... (NYSE: AME ) today announced that it ... of custom, fine-featured components used in the medical device ... in Montevideo, MN, has annual sales of approximately $25 ... of businesses that serve the highly attractive medical device ...
... NEW YORK, April 28, 2011 Reportlinker.com ... is available in its catalogue: ... Healthcare System and Drug Regulatory Overview: Cost-containment ... http://www.reportlinker.com/p0487111/Pharmaceutical-Key-Trends-2011---Healthcare-System-and-Drug-Regulatory-Overview-Cost-containment-and-regulatory-pressures-intensify.html ...
Cached Medicine Technology:AMETEK ACQUIRES AVICENNA TECHNOLOGY 2Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 2Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 3Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 4Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 5Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 6
(Date:6/3/2015)... BC (PRWEB) June 03, 2015 Vancouver ... announced that the firm will now handle personal injury ... Greater Vancouver on the rise, more and more people ... year bus accidents cause needless suffering, serious injury and ... a result of a bus accident in BC you ...
(Date:6/3/2015)... June 03, 2015 Array Health ... technology, has announced that CEO Jonathan Rickert will present ... on June 4, 2015. The session will address ... are disrupting traditional business models in health care, and ... , WHAT: Digital Transformation and the Health Care ...
(Date:6/3/2015)... 2015 A group of nine authors ... a Global Inspire Award at DIA’s upcoming Annual Meeting. ... volunteers for their leadership, level of excellence, and commitment ... The recipients of the Author(s) of the Year Award, ... article has made a significant impact in advancing medical ...
(Date:6/3/2015)... 2015 Z-Medica®, LLC, a leading developer ... has been designated as National Safety Month by the ... Police Department for its commitment to public safety. ... Individual First Aid Kits (IFAK) over 100 times in ... stabbings or traffic accidents. Each kit is equipped with ...
(Date:6/3/2015)... NC (PRWEB) June 03, 2015 Researchers ... two biomarkers for mesothelioma and say the tried-and-true marker ... just posted an article on the research. Click ... the University’s National Center for Asbestos Related Diseases say, ... positive results, it is still preferable to fibulin-3 for ...
Breaking Medicine News(10 mins):Health News:Jiwa Law Corporation Now Handles Personal Injury Claims Involving Bus Accidents 2Health News:Array Health’s CEO to Present at America’s Health Insurance Plans Institute 2015 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 4Health News:Z-Medica Commends Tucson Police Department for Trauma Kit Utilization 2Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2
... Secretary of State Colin Powell, a strong advocate for national ... the world and call upon them to continue their efforts ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081014/DC38855LOGO ) ... the importance and value of volunteerism as part of the ...
... FDA compliant solution that works within minutes to relieve the ... on stings caused by the Portuguese man-of-war. Jellyfish Squish(TM) ... can be purchased online and at select stores including drug ... of 2009 Dr. Peter Verity, a world renowned marine biologist ...
... August and September, PF Week Sept. 14 - 21 ... for Pulmonary Fibrosis (CPF) announced today it has scheduled its 2009 ... The primary goals of this year,s activity are to ensure passage ... of Congress and in communities nationwide. , , Specifically, the ...
... ... ... National HIV Testing Day, June 27, by encouraging people of all ages to learn about HIV, ... vaginal fluids or breast milk. Exposure to any of these fluids can put you at ...
... and Medicare plan participants in Ga. now have access ... , June 25 UnitedHealthcare and ... services of Fusion Sleep,s sleep disorder program available to ... , , "Fusion Sleep provides a very important ...
... French . , Montreal, June 25th 2009 ... have two choices: inject them with medication to dissolve the ... open the blocked artery (primary percutaneous coronary intervention (PCI)). Guidelines ... that do not take "real-life" conditions into account. The latest ...
Cached Medicine News:Health News:Colin Powell Applauds Lions for Leadership in Volunteerism as Interest in Volunteer Service Grows 2Health News:Popular Jellyfish Sting Treatment Also Proven Effective on Stings From Portuguese Man-of-War 2Health News:Popular Jellyfish Sting Treatment Also Proven Effective on Stings From Portuguese Man-of-War 3Health News:CPF Announces Dates for Seventh Annual National Pulmonary Fibrosis Awareness Week 2Health News:CPF Announces Dates for Seventh Annual National Pulmonary Fibrosis Awareness Week 3Health News:CPF Announces Dates for Seventh Annual National Pulmonary Fibrosis Awareness Week 4Health News:Planned Parenthood Recognizes National HIV Testing Day 2Health News:UnitedHealthcare and Fusion Sleep Announce New Agreement 2Health News:Research: Improving treatment of patients with heart attack 2
...
... A wide range of miniTHERM incubators is ... appropriate application solution for their specific requirements. ... liters, are compact and extremely space saving. ... microwave oven. It is possible to stack ...
... miniTHERM incubators is available, ensuring the customers ... their specific requirements. miniTHERM incubators have a ... extremely space saving. Their size corresponds approximately ... possible to stack up to three units ...
... miniTHERM incubators is available, ensuring the customers ... their specific requirements. miniTHERM incubators have a ... extremely space saving. Their size corresponds approximately ... possible to stack up to three units ...
Medicine Products: